C WorldWide Group Holding A S bought a new position in NovoCure Limited (NASDAQ:NVCR) during the second quarter, Holdings Channel reports. The firm bought 273,600 shares of the medical equipment provider’s stock, valued at approximately $4,733,000.

Several other institutional investors have also made changes to their positions in NVCR. Vanguard Group Inc. raised its position in shares of NovoCure Limited by 12.0% in the first quarter. Vanguard Group Inc. now owns 3,047,940 shares of the medical equipment provider’s stock worth $24,688,000 after buying an additional 325,512 shares during the period. Bank of New York Mellon Corp raised its position in shares of NovoCure Limited by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 173,523 shares of the medical equipment provider’s stock worth $1,406,000 after buying an additional 2,480 shares during the period. Geode Capital Management LLC raised its position in shares of NovoCure Limited by 14.6% in the first quarter. Geode Capital Management LLC now owns 128,632 shares of the medical equipment provider’s stock worth $1,041,000 after buying an additional 16,411 shares during the period. River & Mercantile Asset Management LLP acquired a new position in shares of NovoCure Limited during the first quarter worth about $937,000. Finally, Teachers Advisors LLC raised its position in shares of NovoCure Limited by 3.3% in the first quarter. Teachers Advisors LLC now owns 98,799 shares of the medical equipment provider’s stock worth $800,000 after buying an additional 3,125 shares during the period. Institutional investors and hedge funds own 24.96% of the company’s stock.

NovoCure Limited (NVCR) opened at 18.05 on Friday. The company has a 50-day moving average of $18.61 and a 200-day moving average of $12.11. The stock’s market capitalization is $1.61 billion. NovoCure Limited has a 52-week low of $5.95 and a 52-week high of $21.75.

NovoCure Limited (NASDAQ:NVCR) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.01. NovoCure Limited had a negative return on equity of 69.48% and a negative net margin of 75.91%. The company had revenue of $38.38 million during the quarter, compared to analyst estimates of $42.20 million. Equities research analysts expect that NovoCure Limited will post ($0.75) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “C WorldWide Group Holding A S Buys Shares of 273,600 NovoCure Limited (NASDAQ:NVCR)” was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/11/c-worldwide-group-holding-a-s-buys-shares-of-273600-novocure-limited-nasdaqnvcr.html.

NVCR has been the topic of a number of research reports. Zacks Investment Research upgraded shares of NovoCure Limited from a “sell” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Thursday, June 29th. J P Morgan Chase & Co reiterated a “buy” rating and issued a $14.00 price objective on shares of NovoCure Limited in a research report on Monday, May 1st. ValuEngine upgraded shares of NovoCure Limited from a “sell” rating to a “hold” rating in a research report on Saturday, June 3rd. BidaskClub lowered shares of NovoCure Limited from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Finally, Aegis reiterated a “buy” rating and issued a $14.00 price objective on shares of NovoCure Limited in a research report on Tuesday, April 18th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $19.29.

In other NovoCure Limited news, CEO Asaf Danziger sold 180,601 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $15.13, for a total value of $2,732,493.13. Following the sale, the chief executive officer now directly owns 1,163,296 shares of the company’s stock, valued at $17,600,668.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Yoram Palti sold 8,000 shares of the stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $12.05, for a total value of $96,400.00. Following the completion of the sale, the insider now directly owns 55,825 shares in the company, valued at $672,691.25. The disclosure for this sale can be found here. Insiders sold 2,273,522 shares of company stock worth $38,570,172 over the last ninety days. 16.70% of the stock is owned by corporate insiders.

NovoCure Limited Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Want to see what other hedge funds are holding NVCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NovoCure Limited (NASDAQ:NVCR).

Institutional Ownership by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.